What does Z+PHARMA do?

Z+PHARMA is a pharmacy in Beveren-Kruibeke-Zwijndrecht. Public Limited, started on 1 July 1994, 1 establishment.

What is the address of Z+PHARMA?

The registered office of Z+PHARMA is located at Statiestraat 131, 2070 Beveren-Kruibeke-Zwijndrecht.

Is Z+PHARMA still active?

Yes. According to the CBE (29 October 2026) Z+PHARMA is active, legal situation “Normale toestand”, started on 1 July 1994.

Is Z+PHARMA registered on Peppol?

Yes, Z+PHARMA is registered on the Peppol network with ID 0208:0453060967.

What is the enterprise number of Z+PHARMA?

The enterprise number of Z+PHARMA is BE0453060967.

When was Z+PHARMA founded?

Z+PHARMA was founded on 1 July 1994.

Is Z+PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 1 July 1994; 5 annual accounts filed, latest fiscal year 2026; 6 directors known from the annual account.

How much profit did Z+PHARMA make in 2026?

Z+PHARMA recorded a loss after taxes of € 13,886 in financial year 2026.

What is the revenue of Z+PHARMA?

As a small company, Z+PHARMA is not required to publish revenue in its annual accounts. In financial year 2026, its added value was € 412,001.

How much does an employee at Z+PHARMA earn?

The average wage cost per full-time employee at Z+PHARMA was € 68,500 in 2026: staff costs of € 335,448 for 4.9 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does Z+PHARMA have?

According to the 2026 annual accounts, Z+PHARMA has 4.9 full-time equivalents (FTE).

Does Z+PHARMA have a website?

Yes, Z+PHARMA has a website at zpharma.be.

Z+PHARMA (Public Limited) - Beveren-Kruibeke-Zwijndrecht

Q: Who are the directors of Z+PHARMA?

According to the 2026 annual accounts, the directors of Z+PHARMA are: Stefan Goethaert, Jo Willemyns, Kris Castelein, Lichael Hamelrijck, Jozef Colruyt , Stefaan Vandamme.

Dossier Z+PHARMA, printed on 29 October 2026 from databakkes.be/en/0453060967/z-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2026

Z+PHARMA from Beveren-Kruibeke-Zwijndrecht, company number BE0453060967, closed financial year 2026 with a result of € -13,886 after tax. For that financial year Z+PHARMA recorded a gross margin of € 412,001 and equity of € 508,048. Compared with financial year 2025, the result moved from € 26,951 to € -13,886. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 21, 2026.

What it is worth Healthy

€ 508,048

▼ 3% vs 2025

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -13,886

▼ still € 26,951 profit in 2025

Profit after tax over the fiscal year.

Cash in the bank

€ 25,992

▲ 219% vs 2025

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 446,548.

People and assets in 2026

Full-time equivalents

4.9

▲ 0.1 vs 2025

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 335,448

▲ 38% vs 2025

€ 68,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Debts at end 2026

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 211,407

▲ 84% vs 2025

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 16,618

▲ 62% vs 2025

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2024	2025	2026	Change 2025 → 2026
Gross margin	€ 465,770 Gross margin 2022: € 465,770 First fiscal year in the series	€ 655,638 Gross margin 2024: € 655,638 ▲ 41% vs 2022 (€ 465,770) Favourable step	€ 376,566 Gross margin 2025: € 376,566 ▼ 43% vs 2024 (€ 655,638) Unfavourable step	€ 412,001 Gross margin 2026: € 412,001 ▲ 9% vs 2025 (€ 376,566) Favourable step	▲ 9%
Profit after taxes	€ 65,879 Profit after taxes 2022: € 65,879 First fiscal year in the series	€ 195,315 Profit after taxes 2024: € 195,315 ▲ 196% vs 2022 (€ 65,879) Favourable step	€ 26,951 Profit after taxes 2025: € 26,951 ▼ 86% vs 2024 (€ 195,315) Unfavourable step	€ -13,886 Profit after taxes 2026: € -13,886 ▼ € 40,837 vs 2025 (€ 26,951) Unfavourable step	▼ € 40,837
Equity	€ 443,476 Equity 2022: € 443,476 First fiscal year in the series	€ 644,984 Equity 2024: € 644,984 ▲ 45% vs 2022 (€ 443,476) Favourable step	€ 521,934 Equity 2025: € 521,934 ▼ 19% vs 2024 (€ 644,984) Unfavourable step	€ 508,048 Equity 2026: € 508,048 ▼ 3% vs 2025 (€ 521,934) Unfavourable step	▼ 3%
Total debts	€ 772,102 Total debts 2022: € 772,102 First fiscal year in the series	€ 183,011 Total debts 2024: € 183,011 ▼ 76% vs 2022 (€ 772,102) Favourable step	€ 126,485 Total debts 2025: € 126,485 ▼ 31% vs 2024 (€ 183,011) Favourable step	€ 237,991 Total debts 2026: € 237,991 ▲ 88% vs 2025 (€ 126,485) Unfavourable step	▲ 88%
Cash	€ 113,698 Cash 2022: € 113,698 First fiscal year in the series	€ 9,260 Cash 2024: € 9,260 ▼ 92% vs 2022 (€ 113,698) Unfavourable step	€ 8,158 Cash 2025: € 8,158 ▼ 12% vs 2024 (€ 9,260) Unfavourable step	€ 25,992 Cash 2026: € 25,992 ▲ 219% vs 2025 (€ 8,158) Favourable step	▲ 219%
Land & buildings	€ 171,781 Land & buildings 2022: € 171,781 First fiscal year in the series	€ 141,055 Land & buildings 2024: € 141,055 ▼ 18% vs 2022 (€ 171,781) Unchanged	€ 116,618 Land & buildings 2025: € 116,618 ▼ 17% vs 2024 (€ 141,055) Unchanged	€ 92,553 Land & buildings 2026: € 92,553 ▼ 21% vs 2025 (€ 116,618) Unchanged	▼ 21%
Retained profit	€ 431,076 Retained profit 2022: € 431,076 First fiscal year in the series	€ 626,392 Retained profit 2024: € 626,392 ▲ 45% vs 2022 (€ 431,076) Favourable step	€ 460,434 Retained profit 2025: € 460,434 ▼ 26% vs 2024 (€ 626,392) Unfavourable step	€ 446,548 Retained profit 2026: € 446,548 ▼ 3% vs 2025 (€ 460,434) Unfavourable step	▼ 3%
Dividend	€ 65,879 Dividend 2022: € 65,879 First fiscal year in the series	€ 0 Dividend 2024: € 0 ▼ 100% vs 2022 (€ 65,879) Unchanged	€ 150,000 Dividend 2025: € 150,000 Unchanged (€ 0) Unchanged	€ 0 Dividend 2026: € 0 ▼ 100% vs 2025 (€ 150,000) Unchanged	▼ 100%
Bank debt	€ 465,129 Bank debt 2022: € 465,129 First fiscal year in the series	€ 15,092 Bank debt 2024: € 15,092 ▼ 97% vs 2022 (€ 465,129) Favourable step	€ 0 Bank debt 2025: € 0 ▼ 100% vs 2024 (€ 15,092) Favourable step	€ 0 Bank debt 2026: € 0 Unchanged (€ 0) Unchanged
Balance sheet total	€ 1,215,578 Balance sheet total 2022: € 1,215,578 First fiscal year in the series	€ 827,995 Balance sheet total 2024: € 827,995 ▼ 32% vs 2022 (€ 1,215,578) Unchanged	€ 648,420 Balance sheet total 2025: € 648,420 ▼ 22% vs 2024 (€ 827,995) Unchanged	€ 746,039 Balance sheet total 2026: € 746,039 ▲ 15% vs 2025 (€ 648,420) Unchanged	▲ 15%
Employees (FTE)	4.4 Employees (FTE) 2022: 4.4 First fiscal year in the series	4.6 Employees (FTE) 2024: 4.6 ▲ 0.2 vs 2022 (4.4) Unchanged	4.8 Employees (FTE) 2025: 4.8 ▲ 0.2 vs 2024 (4.6) Unchanged	4.9 Employees (FTE) 2026: 4.9 ▲ 0.1 vs 2025 (4.8) Unchanged	▲ 0.1

Key figures of Z+PHARMA, fiscal years 2022 to 2026, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2027) expected before 31 October 2027.

What happened to Z+PHARMA?

What happened at Z+PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Sep 21, 2026 New annual accounts for financial year 2026: loss of € 13,886 (▼ € 40,837 vs 2025). Source: NBB ↗
2026 Lichael Hamelrijck became a director. NBB
2026 Stefaan Vandamme stepped down as director. NBB
2023 Stefan Goethaert became a director. NBB
2023 Jo Willemyns became a director. NBB
2023 Kris Castelein became a director. NBB
2023 Jozef Colruyt became a director. NBB
2023 Stefaan Vandamme became a director. NBB

In short

From € 65,879 profit in 2022 to € 13,886 loss in 2026.

Paid € 82,093 in corporate taxes since 2022.

Best year ever: 2024, with € 195,315 profit.

On average € 84,100 of value added per employee in 2026.

Original PDFs at the National Bank ↗

Management

NEWPHARMA GROUP 100%

The stake of NEWPHARMA GROUP comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

Z+PHARMA

Behind Z+PHARMA are Stefan Goethaert, Jo Willemyns, Kris Castelein, Lichael Hamelrijck and Jozef Colruyt . The shares are held by NEWPHARMA GROUP (100%).

Directors

According to the 2026 annual accounts

Stefan Goethaert

Director

since 2023

Jo Willemyns

Director

since 2023

Kris Castelein

Director

since 2023

Lichael Hamelrijck

Director

since 2026

Jozef Colruyt

Director

since 2023

Stefaan Vandamme

Director

since 2023 · until 2026

Shareholders

NEWPHARMA GROUP

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Statiestraat 131

2070 Beveren-Kruibeke-Zwijndrecht

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

APO@WZC

COSIFARMA

€ 59,346 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTPS zpharma.be

Technologies

Next.jsVercel

Hosting & Email

Email provider

Microsoft 365

Hosting

AMAZON-02 - Amazon.com, Inc., US

Website info

HTTPS Ja

Languages NL

Features

Security

✓ HTTPS

✓ SPF

✓ DMARC

Details

Company number

0453.060.967

VAT number

BE 0453.060.967

Registered office

Statiestraat 131, 2070 Beveren-Kruibeke-Zwijndrecht

Names & denominations

Z+PHARMA

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

1 July 1994

Peppol

Active · Active since 24 Nov 2023

Contact

zpharma.be [email protected] 032528001

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

Z+PHARMA

Financials

What happened to Z+PHARMA?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Website

Technologies

Hosting & Email

Website info

Features

Security

Details

Frequently asked questions